Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354371 | 1.00 | TSHR (0.40) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL354849 | 0.84 | TSHR (0.42) | TSHRTHRBALDH1A1LMNAUSP2 | |
| SCHEMBL356959 | 0.84 | TSHR (0.42) | TSHRTHRBALDH1A1LMNAUSP2 | |
| SCHEMBL355276 | 0.84 | TSHR (0.41) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL452568 | 0.84 | TSHR (0.41) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL356435 | 0.78 | THRB (0.46) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL354284 | 0.78 | THRB (0.46) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL354281 | 0.78 | THRB (0.41) | TSHRTHRB | |
| Trimethylammonium SCHEMBL28049823 | 0.77 | TSHR (0.51) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL354370 | 0.77 | TSHR (0.39) | TSHRTHRBPOLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420709-B2 | Coating composition, (meth)acrylic polymer and monomer mixture for producing the (meth)acrylic polymer | EVONIK RÖHM GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8415422-B2 | (Meth)acrylate monomer, polymer and coating agent | EVONIK RÖHM GMBH (DE) | 2013-04-09 | — | — | US | disclosed |
| US-20120065322-A1 | (METH)ACRYLATE POLYMER, COATING AGENT, METHOD FOR PRODUCING A COATING, AND COATED OBJECT | EVONIK ROEHM GMBH (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20120016071-A1 | POLYFUNCTIONAL (METH)ACRYLIC POLYMER, COATING COMPOSITION, PROCESS FOR PRODUCING A COATING AND COATED ARTICLE | EVONIK ROEHM GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20110144267-A1 | FUNCTIONALIZED (METH)ACRYLATE MONOMER, POLYMER, COATING AGENT, AND PRODUCTION AND CROSS-LINKING METHOD | EVONIK ROEHM GMBH (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110130509-A1 | (METH)ACRYLATE MONOMER, POLYMER AND COATING AGENT | EVONIK ROEHM GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144267-A1 | FUNCTIONALIZED (METH)ACRYLATE MONOMER, POLYMER, COATING AGENT, AND PRODUCTION AND CROSS-LINKING METHOD | DNMT1, TET1, MGMT | TSHR 2023/4885THRB 2750/4885POLB 1667/4885 |
| US-20110130509-A1 | (METH)ACRYLATE MONOMER, POLYMER AND COATING AGENT | MGMT, DNMT1, TET1 | TSHR 1058/4885THRB 1927/4885POLB 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.